The new building is supposed to deliver in 2026. Rendering via UH.edu

Two University of Houston alumni have made a donation supporting a project that will create a central campus hub for innovation activity.

Ali and Emad Lakhany, along with their family, have reportedly donated to their alma mater to support the University’s planned Innovation Hub. The amount of the donation was not disclosed but also contributed to economic inclusivity research at the C. T. Bauer College of Business, according to a UH news release, by establishing the Musa and Khaleda Dakri Center for Economic Inclusion.

With the gift, UH will name the second floor of the building the Salma and Hashim Yousuf Lakhany Entrepreneurship Floor, in honor of the brothers' parents who emigrated from Pakistan in the 1960s.

"My brother Emad, sister Lina, and I are thrilled to make this generous gift to the Bauer College of Business and the University of Houston’s innovation and entrepreneurship initiatives,” says CSM Group CEO Ali Lakhany, a 2007 UH graduate, in the release.

The CSM Group is a Houston company that works in restaurant franchising, telecommunications, hospitality, and real estate development.

“Our parents, immigrants to this country, have always instilled in us a profound belief in the power of entrepreneurship and the importance of giving back. With this contribution towards the Innovation Hub, we are honored to have a floor named after our parents within this remarkable building,” he continues. “We are excited about the boundless opportunities this space will offer to students, entrepreneurs and innovators. Together, we look forward to a future of endless possibilities and positive impact."

Originally reported about by InnovationMap, the UH Innovation Hub is a 75,000 square-foot building to rise on the site of the current Technology Annex building and open in 2026. In it will reside the Cyvia and Melvyn Wolff Center for Entrepreneurship, the Musa and Khaleda Dakri Center for Economic Inclusion, the Energy Transition Institute, a large makerspace, and more.

Ali Lakhany and Emad Lakhany are UH alumni. Photo via uh.edu

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.